How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial (Q64101440)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

title

How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

0 references

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Agnes Bosch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Christian Ott

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Susanne Jung

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Kristina Striepe

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Marina V Karg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Dennis Kannenkeril

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

Thomas Dienemann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

language of work or name

English

0 references

publication date

29 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

Cardiovascular Diabetology

1 May 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

page(s)

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 May 2020

cites work

1 reference

12 December 2020

Expert consensus document on arterial stiffness: methodological issues and clinical applications

1 reference

12 December 2020

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study

1 reference

12 December 2020

Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?

1 reference

12 December 2020

Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study

1 reference

12 December 2020

Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension

1 reference

12 December 2020

Wave reflections, assessed with a novel method for pulse wave separation, are associated with end-organ damage and clinical outcomes

1 reference

12 December 2020

Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements

1 reference

12 December 2020

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

12 December 2020

The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

1 reference

12 December 2020

Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

1 reference

12 December 2020

Comparison of an oscillometric method with cardiac magnetic resonance for the analysis of aortic pulse wave velocity

1 reference

12 December 2020

Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension

1 reference

12 December 2020

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

1 reference

12 December 2020

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

1 reference

12 December 2020

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

1 reference

12 December 2020

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

1 reference

12 December 2020

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

1 reference

12 December 2020

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

1 reference

12 December 2020

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice

1 reference

12 December 2020

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.

1 reference

12 December 2020

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

1 reference

12 December 2020

Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.

1 reference

12 December 2020

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.

1 reference

12 December 2020

EMPA-REG OUTCOME: The Nephrologist's Point of View

1 reference

12 December 2020

Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern

1 reference

12 December 2020

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.

1 reference

12 December 2020

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus

1 reference

12 December 2020

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study

1 reference

12 December 2020

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

1 reference

12 December 2020

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

1 reference

12 December 2020

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

1 reference

12 December 2020

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

1 reference

12 December 2020

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.

1 reference

12 December 2020

Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy.

1 reference

12 December 2020

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice.

1 reference

12 December 2020

Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study

1 reference

12 December 2020

Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors

1 reference

12 December 2020

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

1 reference

12 December 2020

Empagliflozin directly improves diastolic function in human heart failure

1 reference

12 December 2020

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

1 reference

12 December 2020

10.1186/S12933-019-0839-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 May 2020

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/s12933-019-0839-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30922297%20AND%20SRC:MED&resulttype=core&format=json

1 May 2020

PubMed publication ID

30922297

1 reference